Boehringer Ingelheim and GNA Biosolutions partner on emergency veterinary diagnostics development
Programme could lead to new diagnostic solutions for African swine fever.
+49-6132-77 0
Boehringer Ingelheim launches first veterinary vaccines produced in China
The first local manufacturing plant, wholly-owned by a multinational animal health company, focuses on the China swine market.
Boehringer Ingelheim launches a tool to aid in the prevention of African swine fever
This tool enables pig producers to evaluate areas for biosecurity improvement on their farms.
Boehringer Ingelheim announces a pre-signing with Dopharma for the acquisition of its production site in Saint-Herblon, France
Dopharma is a growing player on the market, already distributing in more than 50 countries.
Boehringer Ingelheim inaugurates its new global centre for veterinary vaccine R&D in Lyon, France
The new R&D center of 14,500 square meters is a high-tech facility employing more than 200 employees.
Boehringer Ingelheim invests more than €200 million to establish strategic production center for Veterinary Public Health in France
With this new site, the company will be able to respond to the growing global demand for foot-and-mouth disease and Bluetongue virus control.
Boehringer Ingelheim supports collaboration and knowledge sharing in the livestock industry
The 11th Expert Forum on Farm Animal Well-Being will bring together over 100 veterinary practitioners and welfare specialists.
Boehringer Ingelheim inaugurates its new integrated Asian Veterinary Research & Development Centre
World-class research & development facility of 3,300 square meters will help enhance China’s animal health industry.
Three leading animal health companies join hands to launch world-class vaccine joint venture targeting foot-and-mouth disease in China
Boehringer Ingelheim, KMOH, and ZNWT establish a vaccine joint venture targeting foot-and-mouth disease control and prevention in China.
2018 European PRRS Research Award open for submissions until July 1st
Boehringer Ingelheim funds three research projects against swine disease PRRS with a total of €75,000
Boehringer Ingelheim Invests $80 Million to Expand Animal Vaccine Manufacturing Capacity in the U.S.
Investments in Athens, GA and St. Joseph, MO will enable increased capacity for companion animal and livestock vaccines.
Winners of the 2017 European PRRS Research Award announced
Boehringer Ingelheim Animal Health sponsors the €75,000 research award programme in Europe both to encourage further development of practical methods for controlling PRRS and in order to recognise scientific excellence in this field.
Comprehensive online management biosecurity assessment tool
New tool is part of suite of solutions to improve farm biosecurity and control of PRRS (Porcine Reproductive and Respiratory Syndrome).
Boehringer Ingelheim: A New World Leader in Animal Health
Animal health business, following a positive 2016, is poised for strong long-term growth and industry leadership after strategic addition of Merial.
Boehringer Ingelheim presents a new tool to assess and monitor biosecurity and management risks in pig farms
Biosecurity in pig farms plays a key role in PRRS control and some of the recommendations depend on the movement and flow of certain pathogen-carrying agents like people or objects.
Boehringer Ingelheim Animal Health has been supporting independent research on PCV2 for one decade
Over the past ten years, 29 research projects have been awarded with € 25,000.
2017 European PRRS Research Award: Boehringer Ingelheim Animal Health calls for submissions until July 1st
Boehringer Ingelheim Animal Health funds three research projects for improved control of swine disease PRRS with a total of 75,000 euros
Proven and reliable efficacy: 4 Billion Pigs Protected against M. hyo, PCV 2 and PRRS with vaccines from Boehringer Ingelheim Animal Health
Ingelvac MycoFLEX® is one of the leading vaccines for the control of Mycoplasma hyopneumoniae globally
Ingelvac CircoFLEX®: two billion pigs protected against PCV2
Worldwide over two billion pigs have been protected against Porcine Circovirus Disease using Ingelvac CircoFLEX®
Three projects win 2016 European PRRS research award
Boehringer Ingelheim Animal Health has sponsored European PRRS Research Award for the third time. The main aim of this award is to encourage research in the field of PRRS.
Boehringer Ingelheim announces agreement with Ceva Santé Animale for the sale of certain Merial assets
Through this important step Boehringer Ingelheim aims to facilitate the approval process for Boehringer Ingelheim’s acquisition of Sanofi’s animal health business, Merial, by proactively offering up this divestiture to Ceva. Ceva will acquire certain animal health vaccines and pharmaceuticals from the Merial portfolio for swine, bovine and companion animals as well as related intellectual property, manufacturing processes and R&D activities.
Contact:
Contact us using the following form.